arrow
B

Brian Weiss

indiana university school of medicine
H指数:37
被引数:5,917

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series

MEK抑制剂治疗期间恶性周围神经鞘瘤的发展:一项预临床研究和临床病例系列

2026-07-110
OA
The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma

参与者在进行MEK抑制剂临床试验的丛状神经纤维瘤中致病性NF1变异的谱系

2025-10-150
PRE
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
CANCER
IF5.1
2025-02-110
PRE
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results (vol 29, pg 1379, 2023)
2024-01-090
OA
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results

Car-nkt细胞在复发或难治性神经母细胞瘤中的Anti-GD2: 更新的1期试验中期结果

2023-05-1556
PRE
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas

在无法手术的丛状神经纤维瘤的1/2期试验中,司美替尼对1型神经纤维瘤患儿的长期安全性和有效性

2023-04-2826
OA
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus

1型神经纤维瘤病表现的MEK抑制剂: 临床证据和共识

2022-07-0539
OA
Management of neurofibromatosis type 1-associated plexiform neurofibromas

1型神经纤维瘤病相关丛状神经纤维瘤的管理

2022-06-0354
OA
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity
2022-04-2521
OA
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
2022-04-0856
OAAI
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1
2021-06-0120
OAAI
Selumetinib in Children with Inoperable Plexiform Neurofibromas
2020-04-09391
OAAI
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas
2016-12-29472
OAAI